版本:
中国

BRIEF-Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial

May 10 Evoke Pharma Inc:

* Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial as late breaker at digestive disease week 2017

* Says safety data from phase 3 trial were consistent with favorable results from previous gimoti studies

* Evoke Pharma - based on recent fda discussions, these data are anticipated to be submitted as part of a new drug application for Gimoti

* Says trial data was not statistically significant in itt group

* Evoke Pharma - patients, which 51pct enrolled in study, responded clinically and statistically significantly better to gimoti than placebo Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐